Axiom Biosciences targets Hong Kong IPO to raise up to $200 million for regenerative therapy pipeline

Axiom Biosciences, a San Diego‑based biotech, announced plans to list on the Hong Kong Stock Exchange rather than the traditional U.S. exchanges. The company aims to use the offering to secure new capital and expand its global footprint.

The IPO, slated for next year, is expected to raise between $150 million and $200 million. Proceeds will be directed toward accelerating the development of its regenerative medicines pipeline, according to CEO and founder Remo Moomiaie‑Qajar.

The move follows a recent rebrand from Cytonus Therapeutics to Axiom Biosciences. It also comes on the back of Phase 1 data for the company’s lead stem‑cell therapy, developed with South Korea’s Medinno, which showed a one‑year survival rate of 100% in nine newborns with severe brain injuries, compared with a historical 46% mortality rate for similar cases.